INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly inhibits tumor growth, extends survival and increases cure rates even after end of treatmentINV501 is an orally available compound with good bioavailability and favorable pharmacokinetic profile VIENNA, Austria, June 19, 2023 (GLOBE NEWSWIRE) invIOs GmbH (“invIOs”), a privately held biotechnology company develop
EQS-News: invIOs GmbH: invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Houses and car torched in targeted arson attacks following drugs gang dispute manchestereveningnews.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from manchestereveningnews.co.uk Daily Mail and Mail on Sunday newspapers.